

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

2124-311

Total Pages

48

First Named Inventor or Application Identifier

Shiuan CHEN et al.

Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification Total pages [29]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross references to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings
 - Detailed Description
 - Claims
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) (Total Sheets) [12]
4. ☐ Oath or Declaration (Total Pages) ☐
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application
(37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
5. ☐ Incorporation by Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)

ADDRESS TO: Assistant Commissioner of Patents
Box Patent Application
Washington, D.C. 20231

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee)
- ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement /PTO 1449
☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity Statement(s)
☐ Statement Filed in prior application, Status still proper and desired
15. ☐ Certified Copy of Priority Document(s).
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label or ☒ Correspondence address below
(Insert Customer No. or Attach bar code label here)

Name	Stephen A. Saxe, Ph.D., Reg. No. 38,609 <i>Stephen A. Saxe</i>				
Address	Rothwell, Figg, Ernst & Kurz Suite 701-East, 555 13th Street, N.W. 19 April 2000				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

5/1 Page 550

10/52 U.S. PTO

09/552705



04/19/00

10/52 U.S. PTO

TITLE OF THE INVENTION

DRUG SCREENING USING A PROLINE-RICH NUCLEAR RECEPTOR
CO-REGULATORY PROTEIN/NUCLEAR RECEPTOR CO-EXPRESSION SYSTEM

5 CROSS REFERENCE TO RELATED APPLICATIONS

The present invention is related to provisional application Serial No. 60/129,873 filed 19
April 1999, which is incorporated herein by reference.

10 This application was made with Government support under Grant Nos. CA44735 and
ES08258, funded by the National Institutes of Health, Bethesda, Maryland. The federal
government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

15 Steroid hormones, including estrogens, play an essential role in metabolism, sexual
differentiation, and reproductive function. Considerable attention, therefore, has been directed
to defining the mechanisms that control their biosynthesis. We have been studying the
mechanisms that regulate the expression of the human aromatase gene in breast cancer.
Aromatase catalyzes the conversion of androgens to estrogens and plays a key role in the
pathogenesis of hormone-dependent breast cancer. An understanding of the mechanisms that
20 regulate expression of the human aromatase gene will allow one to develop assays to screen for
drugs for treating or preventing breast cancer, e.g., by screening for drugs which positively or
negatively modulate transcription of the aromatase gene. Research from our laboratory has
identified a silencer element (Wang and Chen, 1992; Zhou and Chen, 1998) that is situated
between two aromatase promoters, 1.3 (Zhou et al., 1996a) and II (Wang and Chen, 1992; Zhou
25 and Chen, 1998), which are thought to be the major promoters controlling aromatase expression
in the ovary and in breast cancer tissue (Zhou et al., 1996b; Harada, 1997; Agarwal et al., 1996).
UV cross-linking experiments (Wang and Chen, 1992; Zhou and Chen, 1998) have found that
at least four proteins bind to the silencer element. Two orphan nuclear receptors, SF1
(Steroidogenic factor 1) and ERR α 1 (Estrogen related receptor α -1), were shown to bind to this
30 regulatory region (Yang et al., 1998). Cell transfection experiments have revealed that both SF1
and ERR α 1 function as positive regulatory factors when they bind to the silencer element (Yang
et al., 1998).

Nuclear receptors are transcription factors that modulate transcription of various cellular genes, either positively or negatively, by interacting with specific hormone-responsive elements located in the target gene promoters and thereby control diverse aspects of cell growth, development, and homeostasis. The mechanisms by which the nuclear receptors can regulate the transcription from the target gene promoters are currently under intensive investigation. Recent data show that, in addition to contacting the basal transcriptional machinery directly, nuclear receptors enhance or inhibit transcription by recruiting an array of coactivator and corepressor proteins to the transcription complex. Recently, a number of these putative co-regulatory proteins for nuclear receptors have been identified, and have been shown to act either as coactivators or as corepressors (reviewed in Horwitz et al., 1996; Shibata et al., 1997; Glass et al., 1997). Among the members of a growing family of coactivators are CBP and members of the SRC-1 gene family including SRC-1/pl60 (Onate et al., 1995; Halachmi et al., 1994; Kamei et al., 1996), TIF2/GRIP-1 (Voegel et al., 1996; Hong et al., 1996; Ding et al., 1998), and CBP/p300 (Chakravarti et al., 1996; Hanstein et al., 1996) which function as coactivators of nuclear receptors, and also RIP140 (Cavailles et al., 1994; Cavailles et al., 1995), TIF1 (Le Douarin et al., 1995) and TRIP1/SUG-1 (Lee et al., 1995; vom Baur et al., 1996), the functions of which are not clearly defined. Most of these cofactors of nuclear receptors have a molecular weight around 160 kDa, and share a common motif containing a core consensus sequence LXXLL (L, leucine; X, any amino acid), which is necessary and sufficient to mediate the binding of these proteins to liganded nuclear receptors. LXXLL is thus a defining feature of pl60 coactivators (Heery et al., 1997).

Although these cofactors are of interest, additional co-activators and co-repressors are sought, especially those which interact with receptors via a novel binding motif.

The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice are incorporated by reference and for convenience are respectively grouped in the appended List of References.

SUMMARY OF THE INVENTION

A protein named proline-rich nuclear receptor co-regulatory protein (PNRC) (SEQ ID NOs:7 and 8 represent the gene and protein sequences of PNRC) has been found to be a novel type of nuclear receptor coactivator which binds to nuclear receptors including those which

regulate the human aromatase gene which is involved in development of breast cancer. PNRC binds to nuclear receptors via a different motif than that of a number of known coactivators. As a result, drug screening assays utilizing PNRC will result in finding of useful drugs, such as for treating breast cancer, which would be missed by screens using a different class of nuclear receptor coactivator.

One aspect of the invention is a method of screening a chemical for its ability to enhance the binding of a co-regulatory protein to a nuclear receptor or to a nuclear receptor ligand binding domain. More particularly, this aspect of the invention is directed to screening a chemical by cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding a nuclear receptor or a nuclear receptor ligand binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain, growing separate portions of the cotransfected cells in the presence and in the absence of said chemical, and determining the level of expression of the reporter gene in each portion of cotransfected cells to determine whether the chemical enhances binding of the co-regulatory protein to the nuclear receptor or to the nuclear receptor ligand binding domain.

A second aspect of the invention is a method of screening for a chemical for its ability to inhibit the binding of a co-regulatory protein to a nuclear receptor or to a nuclear receptor ligand binding domain. More particularly, this aspect of the invention is directed to screening a chemical by cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding a nuclear receptor or a nuclear receptor binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain, growing separate portions of the cotransfected cells in the presence and in the absence of said chemical, and determining the level of expression of the reporter gene in each portion of cotransfected cells to determine whether the chemical

inhibits binding of the co-regulatory protein to the nuclear receptor or to the nuclear receptor ligand binding domain.

A third aspect of the invention is a method of screening a chemical to determine if it has activity similar to a known chemical such as a hormone. More particularly, this aspect of the invention is directed to screening a chemical by cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding a nuclear receptor or said nuclear receptor ligand binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said known chemical, growing a first portion of said cotransfected cells in the presence of said test chemical, growing a second portion of said cotransfected cells in the absence of said chemical, and determining the level of expression of said reporter gene in each portion of cells to determine whether the test chemical results in reporter gene expression similar to the expression produced by the known chemical.

Another aspect of the invention is a method of determining a concentration of a ligand or a hormone in a tissue sample. More particularly, this aspect of the invention is directed to determining a concentration of a ligand or a hormone in a tissue sample, wherein said method comprises cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding a nuclear receptor or said nuclear receptor ligand binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said ligand or hormone, preparing an extract of said tissue sample, growing a first portion of said cotransfected cells in the presence of said tissue extract, growing second portions of said cotransfected cells in the presence of known concentrations of said ligand or hormone, and

determining the level of expression of said reporter gene in each portion of cells, wherein the concentration of said ligand or said hormone in said tissue extract can be determined by comparison of the expression level of said reporter gene in said first portion with the expression levels of said reporter gene in said second portions.

Another aspect of the invention is a method of using a two-hybrid screening assay to screen a library for a gene encoding a protein which binds to a specific chemical. More particularly, this aspect of the invention is directed to a method of screening for a protein which interacts with a chemical, wherein said method comprises cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a library of nucleic acids to produce a library of cotransfected cells which synthesize said co-regulatory protein and said library of nucleic acids, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to a nuclear receptor or to a nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said chemical, growing colonies of said cotransfected cells in the presence of said chemical, and determining the level of expression of said reporter gene in individual colonies of cells, wherein colonies of cells which express said reporter gene comprise a gene from said library encoding a protein which interacts with said chemical.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A-C show the interaction between PNRC and nuclear receptors in yeast. Yeast strains Y187, expressing the Gal4DBD fusion to the nuclear receptors, and CG1945, expressing Gal4AD alone or Gal4Ad- PNRC fusion protein, were mated by coculture, and selected for the presence of both two-hybrid plasmids. The expression of interacting hybrid proteins in yeast diploids was analyzed for induction of HIS3 expression (Figure 1A) and *LacZ* expression (Figures 1B and 1C) in the presence of the indicated amount of ligands as described in Example 1. Gal4AD was included as a control to monitor the background transcriptional activity. Relative β -galactosidase activities in liquid cultures were expressed in OD₄₂₀ as mean \pm S.D. of three independent assays. Hormones used in Figures 1B and 1C are the same as for Figure 1A.

Figure 2 shows the interaction of PNRC with SF1 in mammalian cells. SK-BR-3 cells were transiently cotransfected with 1.5 μ g reporter plasmid, pG5CAT, and 1.0 μ g each of

expression plasmids for SF1 and wild type PNRC or for PNRC fragments. The relative CAT activities were expressed as mean \pm S.D. of three experiments.

Figures 3A-B show the interaction of PNRC with SF1 *in vitro*. ³⁵S-labeled, *in vitro* translated SF1 was incubated with Sepharose beads containing bound GST-PNRC₂₇₀₋₃₇₇, GST-PNRC₂₇₈₋₃₀₀, or GST protein. The beads were washed and bound protein was eluted and analyzed by SDS-PAGE. The gel was stained with Coomassie blue (Figure 3B) before being visualized by autoradiography (Figure 3A). An aliquot of the *in vitro* translated SF1 equivalent to 10% of sample employed for the binding reactions was also analyzed (input).

Figures 4A-D show the effect of PNRC on nuclear receptor transactivation function. Figure 4A shows the effect of PNRC on SF1-stimulated transcription of promoter 1.3 of the human aromatase gene. SK-BR-3 cells were transfected with 2.5 μ g of p1.3aroCAT-(SF1site)₃ reporter along with 5 ng of a pSG5-SF1 expression plasmid and an amount of pSG5-PNRC expression plasmid as indicated below the figure. Appropriate amounts of empty vector, pSG5, were included to maintain the overall same amount of total DNA in all transfections. The CAT activities in transfected cells were measured as described in Example 5, and expressed as mean \pm S.D. of at least triplicate experiments. Figure 4B shows the effect of PNRC on ERR α 1-stimulated transcription of promoter 1.3 of the human aromatase gene. SK-BR-3 cells were transfected with p1.3CAT-(SF1site)₃ reporter along with either pSG5-ERR α 1 expression plasmid, pSG5-PNRC or both as indicated below the figure. All other features are as described in Figure 4A. Figure 4C shows the effect of PNRC on SF1-mediated transcription of thymidine kinase promoter. SK-BR-3 cells were transfected with ptkCAT-(SF1 site)₃ reporter along with either pSG5-SF1 expression plasmid, pSG5-PNRC expression plasmid, or both as indicated below the figure. All other features are the same as in Figure 4A. Figure 4D shows the effect of PNRC on ERR α 1-mediated transcription of thymidine kinase promoter. SK-BR-3 cells were transfected with ptkCAT-(SF1site)₃ reporter along with either pSG5-ERR α 1 expression plasmid, pSG5-PNRC expression plasmid, or both as indicated below the figure. All other conditions are the same as in Figure 4A.

Figure 5A shows the localization of the interacting domain within PNRC. A series of N-terminal deletion mutants of PNRC were generated and tested for interaction in yeast two-hybrid assays with different nuclear receptors. Gal4 AD-PNRC deletion constructs were cotransformed with Gal4DBD-nuclear receptor into yeast strain Y187 and transformants bearing

both hybrid plasmids were selected and propagated in the presence of appropriate ligands. The β -galactosidase activities in yeast were determined, expressed in average OD₄₂₀ of three independent assays, the results being shown in Figure 5B.

Figure 6 shows a mutational analysis of the core ligand motif for the SH3 domain in PNRC. The yeast expression plasmid pACT2-PNRC 278-300 (mutant) was prepared as follows: two complementary oligonucleotides with the coding sequences for PNRC278-300 carrying double mutations P287A and P290A were synthesized, annealed, and cloned into pACT2 vector through an *EcoRI* site. Yeast strain Y187 was cotransformed with pACT2-PNRC₂₇₈₋₃₀₀ (wildtype), or pACT2-pNRC₂₇₈₋₃₀₀ (mutant), along with each type of the Gal4DBD fusion protein expression plasmids for SF1, PR_{HBD}, TR_{HBD}, RAR_{HBD}, and RXR_{HBD}. The Y187 transformants carrying both plasmids were cultured in YPD medium containing a proper ligand (for SF1, no ligand), and the β -galactosidase activity in these cells was determined.

DETAILED DESCRIPTION OF THE INVENTION

In order to better understand the regulatory mechanism of nuclear receptors and hormone binding domains such as SF1, ERR α 1, ER AR, PR, TR, RAR and RXR on aromatase expression, a search was made for co-regulatory proteins interacting with these proteins using bovine SF1 as the bait in a yeast two-hybrid screening of a human mammary gland cDNA expression library. This search resulted in the isolation of several clones, one of which encodes a protein named proline-rich nuclear receptor co-regulatory protein (PNRC).

PNRC was previously named B4-2 and was first isolated by differential screening of a human natural killer (NK) cell line library (Chen et al., 1995), and then its rat homologue was isolated from a rat bronchiolar epithelial cell cDNA library (Bingle, 1996). *PNRC* encodes a deduced 327 aa protein (SEQ ID NO:8) with a calculated molecular mass of 35 kDa. This protein exhibits interesting structural features. It is very rich in proline, from 13.4% in human PNRC to 14.4% in the rat homologue. The exact function of proline rich regions in proteins remains unclear. However, in many proteins it appears that they mediate functionally important binding reactions (Williamson, 1994). PNRC also contains several SPXX or TPXX sequence motifs; proteins rich in these two motifs are a sign of gene regulatory proteins (Suzuki, 1989). There is a potential nuclear localization sequence located at position 94-101 of PNRC. This sequence is thought to be necessary for nuclear proteins to translocate into the nucleus (Boulikas,

1993). Based on these structural features, PNRC has been postulated to be involved in gene regulation (Chen et al., 1995). In the present study, PNRC was isolated through its interaction with the orphan receptor SF1. The results generated from yeast and mammalian two-hybrid assays, *in vitro* binding assays, and functional analysis have provided several lines of evidence supporting that PNRC is a general co-regulatory protein for the nuclear receptor superfamily.

Unlike most of the coactivators, the interactions of which with the nuclear receptors depend on an LXXLL motif, the interaction between PNRC and the nuclear receptors is dependent on an S-D-P-P-S-P-S (SEQ ID NO:5) core ligand motif for SH3 in a stretch of proline-rich sequence at its carboxy-terminus, aa 278-300 (shown separately as SEQ ID NO:9). This domain was not found in other nuclear receptor coactivators including SRC1, GRIP1, RIP140, TIFI, TIFII, ARA70, and CBP/p300 in a BLAST sequence homology search, suggesting that different parts of the nuclear receptors participate in the formation of the binding interface with PNRC as compared with the parts that participate with the p160 coactivator family the binding site of which is an NR box. This exact 23 amino acid sequence is also found to be present in another protein isolated from the same yeast two-hybrid screening. Taken together, these proteins including PNRC apparently belong to a new family of nuclear receptor co-regulatory proteins. Considering the core ligand motif for SH3 in PNRC, in addition to its function as a nuclear receptor coactivator, PNRC also may play a role in signal transduction since most of the proteins possessing SH3 domains are involved in signal transduction (Pawson, 1995). Furthermore, since PNRC interacts with nuclear receptor LBDs in a ligand-dependent manner, a PNRC/nuclear receptor LBD coexpression system will be useful for screening ligands or drugs that bind to the nuclear receptors. Similarly, such a system is useful for screening for compounds which inhibit binding of ligands to the nuclear receptors. A two-hybrid system including PNRC can be used to screen for compounds which have activity like a known ligand, taking advantage of the fact that the co-regulatory protein binds to the nuclear receptor in a ligand dependent manner. Assays with PNRC can also be developed to measure ligand or hormone concentration in a tissue. Also, PNRC can be used as the bait in conjunction with a ligand in assays to find other proteins which interact with the ligand. In addition, since PNRC interacts with nuclear receptors in a different fashion from other known co-regulatory proteins (that use the NR box), the ligands or proteins identified using the PNRC/nuclear receptor LBD co-expression system may not be the same as those identified by the traditional approaches. PNRC interacts strongly

with TR, PR and RXR and so the identified ligands for these nuclear receptors may be important modulators of the action of these nuclear receptors in cells. The co-expression system can be developed using, e.g., yeast or mammalian cell culture.

The nuclear receptor binds to its target gene, e.g., aromatase, in conjunction with the co-regulatory protein and a ligand. The ligand is required for the co-regulatory protein to bind to the nuclear receptor. When the ligand, co-regulatory protein and nuclear receptor are bound to the target gene, the target gene activity is affected. This can be a positive regulation or a negative regulation depending upon the specific gene being regulated. Chemicals which act as ligands to promote the binding of the co-regulatory protein to the nuclear receptor, thereby increasing binding of the nuclear receptor to the target gene, can be discovered by screening chemicals using a two-hybrid assay. In the two hybrid assay, cells are cotransfected with two nucleic acids, one of which encodes the co-regulatory protein and the second of which encodes the nuclear receptor or minimally the nuclear receptor ligand binding domain. Additionally, the cotransfected cells are engineered to include a reporter gene, the expression of which is dependent upon the co-regulatory protein binding to the nuclear receptor or to the nuclear receptor ligand binding domain. When the cotransfected cells are grown in the absence of a ligand the expression of the reporter gene will be minimal. When the cotransfected cells are grown in the presence of a chemical which acts as a ligand to promote the binding of the co-regulatory protein to the nuclear receptor or to the nuclear receptor ligand binding domain, the expression of the reporter gene will be increased as compared to its expression level when the cells are grown in the absence of any effective ligand. Many different reporter genes have been reported in the literature and are known to those of skill in the art. For example, genes which cause the production of histidine have been used as reporter genes. The CAT gene is also widely used as a reporter gene.

These assays can be designed to screen for chemicals which act as known ligands. For example, PNRC interacts with hormone binding domain ER when estradiol is present. A two-hybrid system utilizing cells which express PNRC and ER will synthesize a reporter gene in the presence of estradiol but not in the absence of estradiol. Chemicals which can act as estradiol causing PNRC and ER to interact can be screened in a two-hybrid assay in which the cells express PNRC and ER but are grown in the absence of estradiol and in the presence of a test chemical. If the test chemical causes expression of the reporter gene then the test chemical will have estradiol-like activity. Similarly, assays for screening chemicals which will act as other

ligands, e.g., deoxycorticosterone, dihydrotestosterone, progesterone, T3, all-*trans*-retinoic acid or 9-*cis*-retinoic acid, can be developed by preparing a two-hybrid system which expresses PNRC and a hormone binding domain appropriate for the hormone, e.g., GR, AR, PR, TR, RAR or RXR.

Similarly, this same two-hybrid assay system can be utilized to screen for chemicals which inhibit the binding of the co-regulatory protein to the nuclear receptor. This latter method of screening is preferably performed in the presence of a ligand which is known to promote the binding of the co-regulatory protein to the nuclear receptor, thereby resulting in a high expression of the reporter gene. In such an assay, chemicals which decrease the expression of the reporter gene are selected as those which inhibit the binding of the co-regulatory protein to the nuclear receptor.

Assays to measure ligand or hormone concentrations in tissue, e.g., in breast tissue, can be performed using PNRC in a two-hybrid assay. Knowledge of specific hormone levels is often important when treating disease, e.g., knowledge of estrogen levels is important when treating breast cancer. Because of the requirement for a ligand to allow the interaction between PNRC and a nuclear receptor, a two-hybrid assay system can be developed in which the cells are cotransfected to express PNRC and a specific receptor. In the absence of added ligand or hormone the cells will not express the reporter gene. Addition of a tissue extract, containing an unknown concentration of ligand or hormone, to the cells of the two-hybrid assay will result in the expression of the reporter gene if the ligand or hormone required for interaction of PNRC and the nuclear receptor is present in the tissue extract. The concentration of the ligand or hormone can be calculated from the amount of expression of the target gene by comparing the results to expression of the target gene using known concentrations of the ligand or hormone.

PNRC is also useful in performing assays to discover proteins or receptors which interact with ligands or hormones. As an example, tamoxifen is used to treat breast cancer but often resistance to the drug develops. This resistance may develop as a result of a protein being expressed which binds to the tamoxifen. To screen for such a protein, a two-hybrid system is designed in which PNRC is used as the bait. The assay is designed such that cells are cotransfected with PNRC and with a library of other genes. These are grown in the presence of tamoxifen. Cells are assayed for the expression of a reporter gene. A cell-type which expresses the reporter gene is cultured and assayed to determine the gene which it contained. This gene

will encode a protein which interacts with PNRC and tamoxifen. Such an assay allows one to screen for proteins which interact with a ligand. This is different from the typical two-hybrid assay which is used to find two proteins which interact with each other rather than to find a protein and a ligand which interact with each other.

5 The present invention is further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below are utilized.

Example 1

Yeast Two-hybrid Assays

10 The protein-protein interactions between the full-length PNRC or PNRC fragments and SF1, ERR α 1, and several other nuclear receptors were analyzed by yeast two-hybrid assays. The yeast two-hybrid assay was used to test if PNRC also interacts with other members of the nuclear receptor superfamily. pGBT9-ERR α -1 yeast expression plasmid was prepared by inserting the PCR-amplified ERR α -1 coding region into pGBT9 through an *Eco*RI site. To construct the plasmid pGBT9-ER₂₇₄₋₅₉₅, the coding sequence from amino acids 274 to 595 (LBD) of ER α was amplified by PCR with the sense primer 5'-GCCGAATTCGGGGAGGGCAGGGGTGAAGTG-3' (SEQ ID NO:1) and antisense primer 5'-GGCGTCGACGGATCCTCAGACTGTGGCAGGGAAACCCTC-3' (SEQ ID NO:2) and cloned into the *Eco*RI/*Sal*I site of the pGBT9 yeast expression plasmid. pSG5-GRIP1 and several yeast expression plasmids coding for fusion proteins of Gal4-DBD and HBDs of AR, GR, PR, TR, RAR, and RXR in pGBT9 vector were kindly provided by Dr. Michael R. Stallcup (University of Southern California, Los Angeles, CA) (Voegel et al., 1996; Hong et al., 1996; Ding et al., 1998). The yeast mating approach was used in yeast two-hybrid assays to study protein-protein interactions as described in Clontech's protocol. Briefly, pGBT9 (DNA-BD vector only), pGBT9/target plasmids for SF1, ERR α 1, and other HBDs of nuclear receptors, and DNA-BD/control plasmids (as negative control) were introduced into the reporter strain Y187, and the AD vector alone or wild type PNRC and its deleted fragments-containing pACT2 derivatives were used to transform yeast strain CG1945. The yeast mating was performed by picking one colony from each type and growing both colonies in liquid YPD medium with or without a proper ligand at the following concentrations: 100 nM of estradiol for ER; 10 μ M of deoxycorticosterone for GR; 100 nM of

dihydrotestosterone for AR; 500 nM of progesterone for PR; 10 μ M of T3 for TR; 10 μ M of all-*trans*-retinoic acid for RAR; and 10 μ M of 9-*cis*-retinoic acid for RXR. The same amount of an aliquot of the mating culture was spread on both SD/-Leu/-Trp plates to select diploid strains bearing both plasmids and SD/-Leu/-Trp/-His/+3-AT plates to score the growth of the diploid cells that express the two interacting target proteins. The His3 positive colonies were further analyzed for β -galactosidase activity by liquid β -galactosidase activity measurement as essentially described in the protocol.

Yeast strains Y187 expressing the Gal4DB fusion to the nuclear receptors and CG1945 expressing Gal4AD alone or Gal4AD-PNRC fusion protein were mated by co-culturing, and selected for the presence of both two-hybrid plasmids. The expression of interacting hybrid proteins in yeast diploids was analyzed to determine if there was induction of HIS3 expression as shown in Figure 1A and LacZ expression as shown in Figures 1B and 1C. Tests in yeast two-hybrid assays indicated that PNRC interacted with orphan receptors SF1 and ERR α 1 in the absence of any added activator or ligand. As shown in Figures 1A-C, PNRC also interacted specifically with all seven nuclear receptor HBDs, including ER, AR, GR, TR, PR, RAR and RXR, and these interactions were completely ligand-dependent. The results also showed that PNRC interacted with these nuclear receptors with different preferences. PNRC interacts strongly with TR, PR, and RXR in the presence of cognate ligands (Figure 1C), whereas only weak interactions were detected between PNRC and ER, GR, AR and RAR (Figure 1B). However, no interactions occurred either between PNRC and an irrelevant protein such as human lamin C protein or between nuclear receptors and Gal4 activation domain alone. These results suggest that the interaction occurred only in the presence of PNRC and nuclear receptors in the forms of two-hybrid proteins and that PNRC is a broad nuclear receptor-interacting protein which preferentially associates with ligand-bound nuclear receptors.

Example 2

Mammalian Two-hybrid Assays

The Mammalian MatchMaker two-hybrid assay system (Clontech) was used to confirm the interaction between PNRC and SF1 that was identified in the yeast assays. Because the assays are performed in mammalian cells, proteins are more likely to be in their native conformations, and the results are therefore more likely to represent biologically significant

interactions. SK-BR-3 breast cancer cells were cotransfected with three expression plasmids, including pM-SF1 for Gal4 DNA-DB/SF1 fusion protein, pVP16-PNRC for VP16AD-PNRC fusion protein, and a third vector, pG5CAT, to provide the Gal4 DNA-binding site, a promoter, and the CAT reporter gene.

5 A set of plasmids, named pM-SF1, pVP16-PNRC, pVP16-PNRC₂₇₀₋₃₂₇, and pVP16-PNRC₂₇₈₋₃₀₀, for mammalian two-hybrid assays were prepared as follows: SF1 cDNA fragment was excised from pGBT9-SF1 and inserted in frame into Gal4 DNA-binding domain vector pM (Clontech) through an *EcoRI* site. PCR was used to generate PNRC full length coding region as well as the above mentioned deleted fragments with *BclI* at both ends. The PCR products
10 were digested with *BclI* and inserted in proper reading frame into a pVP16 activation domain vector (Clontech) at a *BamHI* site. Mammalian two-hybrid assays in SK-BR-3 cells were performed according to the procedures described in the Clontech protocol (PT3002-1).

As shown in Figure 2, the CAT activities of the cells transfected with the above three plasmids are about 5-6 fold higher than that of the cells transfected with only CAT reporter plasmid. This interaction of PNRC is specific for SF1 since no interaction was observed either
15 between PNRC and Gal4 DB or between SF1 and VP16 AD.

Example 3

GST Pull-down Assays

20 To further confirm the interaction between PNRC and SF1 which was detected in both the yeast and the mammalian two-hybrid assays, a GST pull-down binding assay was performed to study the direct binding between PNRC and SF1 *in vitro*. The PNRC cDNA fragments were generated by PCR and inserted into *E. coli* expression vector pGEX2TK (Pharmacia) through a *BamHI* site to express GST-PNRC wild type and deletion mutants fusion proteins. Wild type
25 bovine SF1 cDNA in pSG5 vector was translated *in vitro* in the presence of [³⁵S]methionine using the TNT Coupled Reticulocyte Lysate System (Promega, Madison, WI). GST and deleted PNRC fusion proteins, GST-PNRC₂₇₀₋₃₂₇ and GST-PNRC₂₇₈₋₃₀₀, were prepared using the affinity matrix Glutathione Sepharose 4B (Pharmacia) according to the supplier's instructions. The washed beads containing about 10 µg GST fusion protein were incubated for 2 hour at 4°C with
30 4 µl *in vitro* translated, [³⁵S]methionine-labeled SF1 in a total volume of 150 µl incubation buffer (50 mM Kpi, pH 7.4, 100 mM NaCl, 1 mM MgCl₂, 10% glycerol, 0.1% Tween 20, 1.5% BSA)

(Treuter et al., 1998). Beads were collected and washed three times with incubation buffer without BSA. Washed beads were resuspended in 50 μ l of 1xSDS sample buffer, boiled in water for 5 minutes, and pelleted briefly in a microfuge. 25 μ l of the supernatant along with 1/10 of the input, [35 S]methionine-labeled SF1 were then subjected to 10% SDS-PAGE. To control the equal loading of GST fusion proteins, gel was stained with Coomassie blue before being visualized by autoradiography.

Our results from the yeast two-hybrid assays showed that a short 23-residue region in PNRC was sufficient for the interaction between PNRC and the nuclear receptors (explained in detail below). PNRC fragments, including PNRC₂₇₀₋₃₂₇ and PNRC₂₇₈₋₃₀₀, were expressed as fusion proteins with glutathione S-transferase (GST) in *E. coli* BL21, purified with glutathione Sepharose 4B beads, and tested for their ability to bind *in vitro* translated [35 S]methionine-labeled SF1 in pull-down assays. As shown in Figures 3A-B, both GST-PNRC₂₇₀₋₃₂₇ and GST-PNRC₂₇₈₋₃₀₀ were found to bind SF1 (Figures 3A-B, lanes 3 and 4). The results also showed that the binding of SF1 was specific to PNRC, because GST alone only retained very small amounts of labeled SF1 (Figure 3A, lane 2) even when the bead-bound GST protein was in excess as shown by Coomassie blue staining in Figure 3B.

Example 4

Isolation of Clones Encoding Proteins which Interact with SF1

In order to better understand the regulatory mechanism of nuclear receptors and hormone binding domains such as SF1, ERR α 1, ER AR, PR, TR, RAR and RXR on aromatase expression, a search was made for co-regulatory proteins interacting with these proteins using bovine SF1 as the bait in a yeast two-hybrid screening of a human mammary gland cDNA expression library. A Gal4-based yeast two-hybrid system was used to identify proteins encoded in a human mammary gland cDNA library that interact with the bovine SF1. The coding region for the wild type bovine SF1 was first subcloned into a yeast expression vector, pGBT9, and the resulting plasmid, pGBT9-SF1, was used to transform CG1945. The coding region of yeast expression plasmid for DBDG_{Gal4}-SF1 fusion protein, named pGBT9-SF1, was made by inserting PCR-amplified cDNA fragment coding for bovine SF1 into an *Eco*RI site of pGBT9 vector (Clontech). For the two-hybrid screening, yeast strain CG1945 containing pGBT9-SF1 plasmid was transformed with a human mammary gland MATCHMAKER cDNA expression library

(Clontech) in the Gal4 activation domain vector (pACT2, Clontech). Transformants (3.42×10^6) were first screened in the absence of ligand, since the ligand for SF1 is unknown, for HIS3 reporter gene expression and then further screened for β -galactosidase activity. A total of 90 colonies appeared on the histidine dropout plates, 12 of which stained strongly positive when tested for expression of β -galactosidase. Plasmids of the twelve His⁺ and β -galactosidase positive transformants were isolated, and the nucleotide sequences of inserts were determined. The identity of the cDNAs was determined through a homology search against known sequences in GenBank. The database search revealed that 4 out of the 12 clones are identical to a portion of B4-2, a proline-rich protein, which was first cloned from a natural killer minus T cell subtractive library with unknown function (Chen et al., 1995). These clones are here designated as PNRC (Proline-rich Nuclear Receptor Co-regulatory protein). Another three clones are identical to a known nuclear receptor coactivator, RIP140 (Cavailles et al., 1994; Cavailles et al., 1995). In addition to PNRC and RIP140, we also isolated two clones encoding one unknown protein with high homology to PNRC as well as three clones encoding three other unknown proteins.

Example 5

Effect of PNRC on Nuclear Receptor Transactivation

PNRC has been demonstrated to specifically interact with multiple members of the nuclear receptor family *in vivo* and *in vitro*. To examine the possible biological significance of this interaction, the entire PNRC coding region was inserted into a mammalian expression vector, pSG5, and this expression plasmid was used to transiently transfect SK-BR-3 cells along with a reporter plasmid, pUMS1.3CAT-(SF1site)₃, which contains three copies of extended steroid hormone half binding site from the human aromatase gene (5'-CCAAGGTCAGAA-3' (SEQ ID NO:3)), promoter 1.3 of the human aromatase gene, and the CAT reporter gene, along with a second expression plasmid for either SF1 (pSG5-SF1) or ERR α 1 (pSG5-ERR α 1) (Yang et al., 1998).

Plasmid for overexpression of PNRC in mammalian cells was made by inserting PCR-amplified fragment with *Bcl*I at both ends into the *Bam*HI site in pSG5 vector (Stratagene). To construct mammalian expression plasmids for bovine SF1 and human ERR α 1, named pSG5-bSF1 and pSG5-hERR α 1, the coding regions for SF1 and ERR α 1 were amplified by PCR

with an *Eco*RI site at both ends, and inserted into an *Eco*RI site of the pSG5 vector. The CAT reporter plasmid, pUMS1.3CAT-(SF1site)₃, was prepared by inserting 3 copies of SF1 binding site from human aromatase gene, 5'-CCAAGGTCAGAA-3' (SEQ ID NO:3), into pUMS-64/+5CAT (Zhou and Chen, 1999) through a *Hind*III site. The transfection of SK-BR-3 cells and CAT assays were carried out as described previously (Wang and Chen, 1992; Zhou and Chen, 1998; Yang et al., 1998).

As shown in Figures 4A and 4B, both SF1 and ERR α 1 can stimulate the transcriptional function of promoter 1.3 of the human aromatase gene. Expression of PNRC in the cells enhanced both SF1-stimulated and ERR α 1-stimulated transcription by promoter 1.3 although PNRC has an inhibitory effect on the transactivation activity of both orphan receptors at higher concentrations (Figures 4A-B). A similar effect was observed when the promoter in the reporter plasmid was replaced by a thymidine kinase (TK) promoter (Figures 4C and 4D). The enhancement of SF1-stimulated transcription by PNRC was moderate and comparable to that by GRIP1 which is a known coactivator. The moderate enhancement of SF1- and ERR α 1-stimulated transcription by PNRC may be due to the endogenous levels of PNRC in SK-BR-3 cells.

Example 6

Localization of the Interacting Domain within PNRC

The four PNRC clones originally isolated from the yeast two-hybrid screening encoded four C-terminal peptides, aa 141-327, aa 148-327, aa 256-327 and aa 270-327, respectively. All four clones showed similar binding ability in binding to SF1. Even the shortest peptide, aa 270-327, retained the ability of PNRC to interact with SF1 (Figure 5B), suggesting that the region containing residues 270 to 327 is responsible for the interaction with SF1. A short conserved peptide motif LXXLL (referred to as the NR box) has been identified and reported to be necessary and sufficient to mediate the binding of several coactivators to liganded nuclear receptors (Heery et al., 1997). There is one NR box-like sequence, LKTLL (aa 319-323; SEQ ID NO:4), in the very end of the C-terminus in PNRC. To examine if this NR box-like sequence is responsible for the interaction, the PNRC fragment coding for aa 270-317 was generated by PCR, expressed as a fusion protein with Gal4 AD, and tested in a yeast two-hybrid assay for its interaction with SF1. Compared to the shortest PNRC clone isolated from library screening, this

PNRC fragment has a deletion of the last 10-amino acid segment which contains the NR box. As shown in Figure 5B, the interaction intensities, as expressed by β -Gal activity, between PNRC/270-327 or PNRC/270-317 and SF1 are about the same, indicating that the NR box sequence in PNRC is not necessary for the interaction. We also expressed this NR box as a fusion protein with Gal4 AD and tested its interaction with SF1 in yeast. No interaction was observed between the NR box and SF1, suggesting again that this NR box sequence is not responsible for the interaction. To directly confirm our findings, yeast expression plasmid for a Gal4AD and PNRC₃₀₁₋₃₂₇ fusion protein (which contains the NR box) was generated and tested in a yeast two-hybrid assay for its interaction with nuclear receptors. As shown in Figure 5B, this fusion protein could not interact with SF1.

Two additional clones were isolated from the same library screening and found to encode an unknown protein with a regional sequence homology to PNRC. Sequence comparison revealed that there is a 23-amino acid region with 100% identity between PNRC and the novel protein, and this 23 amino acid sequence is within the shortest peptide, i.e., PNRC₂₇₀₋₃₂₇, identified in library screening. This information suggests that the 23-amino acid region, aa 278-300, may be responsible for the interaction. To test if the 23 amino acid region, aa 278-300, is sufficient for interaction, a yeast expression plasmid coding for Gal4AD-PNRC₂₇₈₋₃₀₀ fusion protein was prepared and tested for interaction both in yeast and in mammalian cells. As expected, this 23 amino-acid peptide was found to be able to interact with SF1 (Figure 5B) and all other nuclear receptors. In addition, PNRC/278-300 was also found to retain most of the interaction of full length PNRC to SF1 in the mammalian two-hybrid assay. Furthermore, the physical interaction between this short 23 residue fragment and SF1 was also demonstrated in the GST pull-down assay (Figures 3A-B, lane 4). Together, these results demonstrated that the region from aa278 to aa300 in PNRC is critical and sufficient for interaction with nuclear receptors.

Example 7

Mutational Analysis of the Core Ligand Motif for the SH3 Domain in PNRC

The region from residues 270-327 is rich in proline. Proline-rich sequences have been shown to be targets for binding proteins that contain a Src-homology-3 (SH3) domain (reviewed in Pawson, 1995). Structural and mutagenic analyses of peptide-SH3 complexes (Feng et al.,

1994) show that the core ligand for the SH3 domain appears to be a seven-residue peptide containing the consensus X-P-p-X-P, where X tends to be an aliphatic residue and the two conserved prolines (P) are crucial for high affinity binding (Pawson, 1995) ("P" is a crucial proline and "p" is a noncrucial proline). There is a putative core ligand for SH3, S-D-P-P-S-P-S (aa 285-291 (SEQ ID NO:5)), in the aa 278-300 region of PNRC. The biological significance of the core ligand sequence for the SH3 binding domain in PNRC was investigated by the mutagenesis experiments. Double mutations of P287A and P290A in the putative core ligand for SH3, i.e. S-D-P-P-S-P-S (SEQ ID NO:5) to S-D-A-P-S-A-S (SEQ ID NO:6), in the aa 278-300 region of PNRC almost completely abolished the interactions between PNRC278-300 and the nuclear receptors tested including SF1, PR, TR, RAR, and RXR (Figure 6). This result strongly supports that this SH3-binding motif in the region aa 278-300 is essential for PNRC to interact with the nuclear receptors. However, as shown in Figure 5B, the interaction between PNRC/270-327 and SF1 is stronger than the interaction between PNRC/278-300 and SF1, suggesting that other residues, especially the aa 270-278 region, may also participate in the interaction with SF1.

While the invention has been disclosed by reference to the details of preferred embodiments of the invention, it is to be understood that the disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

LIST OF REFERENCES

Agarwal VR, Bulun SE, Leitch M, Rohrich R and Simpson ER (1996). *J. Clinical Endocrinology and Metabolism* 81:3843-3849.

Bingle CD (1996). *Biochemical and Biophysical Research Communications* 225:877-882.

5 Bouliskas T (1993). *Crit. Rev. Eukaryot. Gene Expr.* 3:193-227.

Cavaillès V, Dauvois S, Danielian PS and Parker MG (1994). *Proc. Natl. Acad. Sci. USA* 91:10009-10013.

Cavaillès V, Dauvois S, L'Horsset F, Lopez G, Hoare S, Kushner PJ and Parker MG (1995). *EMBO J.* 14:3741-3751.

10 Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M and Evans RM (1996). *Nature* 383:99-103.

Chen J, Liu L and Pohajdak B (1995). *Biochimica et Biophysica Acta* 1264:19-22.

Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ and Stallcup MR (1998). *Molecular Endocrinology* 12:302-313.

15 Feng S, Chen JK, Yu H, Simon JA and Schreiber SL (1994). *Science* 266:1241-1247.

Glass CK, Rose DW and Rosenfeld MG (1997). *Current Opinion in Cell Biology* 9:222-232.

Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C and Brown M (1994). *Science* 264:1455-1458.

20 Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R and Brown M (1996). *Proc. Natl. Acad. Sci. USA* 93:11540-11545.

Harada N (1997). *J. Steroid Biochem. and Mol. Biol.* 61:175-184.

Heery DM, Kalkhoven E, Hoare S and Parker MG (1997). *Nature* 387:733-736.

Hong H, Kohli K, Trivedi A, Johnson DL and Stallcup MR (1996). *Proc. Natl. Acad. Sci. USA* 93:4948-4952.

25 Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS and Tung L (1996). *Molecular Endocrinology* 10:1167-1177.

Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK and Rosenfeld MG (1996). *Cell* 85:403-414.

30 Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P and Losson R (1995). *EMBO J.* 14:2020-2033.

Lee JW, Ryan F, Swaffield JC, Johnston SA and Moore DD (1995). *Nature* 374:91-94.

006740"5025550

Onate SA, Tsai SY, Tsai MJ and O'Malley BW (1995). *Science* 270:1354-1357.

Pawson T (1995). *Nature* 373:573-580.

Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ and O'Malley BW (1997).

Recent Progress in Hormone Research 52:141-165.

5 Suzuki M (1989). *J. Mol. Biol.* 207:61-84.

Treuter E, Albrektsen T, Johansson L, Leers J and Gustafsson JA (1998). *Molecular Endocrinology* 12:864-881.

Voegel JJ, Heine MJ, Zechel C, Chambon P and Gronemeyer H (1996). *EMBO J.* 15:3667-3775.

Vom Baur E, Zechel C, Heery D, Heine MJ, Garnier JM, Vivat V, Le Douarin B, Gronemeyer

10 H, Chambon P and Losson R (1996). *EMBO J.* 15:110-124.

Wang J and Chen S (1992). *Molecular Endocrinol.* 6:1479-1488.

Williamson MP (1994). *Biochem. J.*, 297:249-260.

Yang C, Zhou D and Chen S (1998). *Cancer Research* 58:5695-5700.

Zhou D and Chen S (1998). *Arch. Biochem. Biophys.* 353:213-220.

15 Zhou D and Chen S (1999). *Arch. Biochem. Biophys.* 371:179-190.

Zhou D, Clarke P, Wang J and Chen S (1996a). *J. Biol. Chem.* 271:15194-15202.

Zhou C, Zhou D, Esteban J, Jurai J, Siiteri PK, Wilczynski S and Chen S (1996b). *J. Steroid Biochem. and Mol. Biol.* 59:163-171.

WHAT IS CLAIMED IS:

1. A method of screening a chemical for its ability to enhance binding of a co-regulatory protein to a nuclear receptor or to a nuclear receptor ligand binding domain, wherein said method comprises:
 - (a) cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding said nuclear receptor or said nuclear receptor ligand binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain;
 - (b) growing a first portion of said cotransfected cells in the presence of said chemical;
 - (c) growing a second portion of said cotransfected cells in the absence of said chemical; and
 - (d) determining the level of expression of said reporter gene in each portion of cells; wherein if the level of expression of said reporter gene in said first portion of said cells is greater than the level of expression in said second portion of said cells then said chemical enhances binding of said co-regulatory protein to said nuclear receptor or to said nuclear receptor ligand binding domain.
2. The method of claim 1 wherein said co-regulatory protein is 35 kDa.
3. The method of claim 1 wherein said co-regulatory protein comprises SEQ ID NO:9.
4. The method of claim 1 wherein said co-regulatory protein consists of SEQ ID NO:8.
5. The method of claim 1 wherein said nuclear receptor is SF1 or $ERR\alpha 1$.
6. The method of claim 1 wherein said nuclear receptor ligand binding domain is selected from the group consisting of ER, AR, GR, PR, TR, RAR and RXR.

- | Parameter | Value | Unit |
|-----------------------|---------|------|
| Initial concentration | 1.0 | g/L |
| Initial pH | 7.0 | |
| Temperature | 25 | °C |
| Time | 0-120 | min |
| Agitation speed | 150 | rpm |
| Batch size | 100 | mL |
| Adsorbent dose | 0.1-1.0 | g/L |
| Adsorption capacity | 0.1-1.0 | g/g |
| Desorption efficiency | 0.1-1.0 | % |
| Regeneration cycles | 1-5 | |
| Recovery percentage | 0.1-1.0 | % |
| Stability | 0.1-1.0 | % |
| Reproducibility | 0.1-1.0 | % |
| Cost-effectiveness | 0.1-1.0 | % |
| Environmental impact | 0.1-1.0 | % |
| Scalability | 0.1-1.0 | % |
| Flexibility | 0.1-1.0 | % |
| Robustness | 0.1-1.0 | % |
| Reliability | 0.1-1.0 | % |
| Efficiency | 0.1-1.0 | % |
| Performance | 0.1-1.0 | % |
| Quality | 0.1-1.0 | % |
| Quantity | 0.1-1.0 | % |
| Value | 0.1-1.0 | % |
| Cost | 0.1-1.0 | % |
| Time | 0.1-1.0 | % |
| Space | 0.1-1.0 | % |
| Energy | 0.1-1.0 | % |
| Material | 0.1-1.0 | % |
| Human | 0.1-1.0 | % |
| Machine | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1-1.0 | % |
| Society | 0.1-1.0 | % |
| Economy | 0.1-1.0 | % |
| Politics | 0.1-1.0 | % |
| Law | 0.1-1.0 | % |
| Education | 0.1-1.0 | % |
| Health | 0.1-1.0 | % |
| Environment | 0.1 | |

13. The method of claim 12 wherein said co-regulatory protein is 35 kDa.
14. The method of claim 12 wherein said co-regulatory protein comprises SEQ ID NO:9.
15. The method of claim 12 wherein said co-regulatory protein consists of SEQ ID NO:8.
16. The method of claim 12 wherein said nuclear receptor is SF1 or $ERR\alpha 1$.
17. The method of claim 12 wherein said nuclear receptor ligand binding domain is selected from the group consisting of ER, AR, GR, PR, TR, RAR and RXR.
18. The method of claim 12 wherein said nuclear receptor comprises a binding domain selected from the group consisting of TR, PR and RXR.
19. The method of claim 12 wherein expression of said reporter gene causes production of histidine.
20. The method of claim 12 wherein said reporter gene is CAT.
21. The method of claim 12 wherein said cells are yeast cells or human cells.
22. The method of claim 12 wherein said nuclear receptor is capable of binding to an aromatase gene.
23. The method of claim 12 wherein a ligand which enhances binding of said co-regulatory protein to said nuclear receptor or to said nuclear receptor ligand binding domain is present.
24. The method of claim 23 wherein said ligand is estradiol, deoxycorticosterone, progesterone, dihydrotestosterone, T3, all-*trans*-retinoic acid or 9-*cis*-retinoic acid.

25. A method of screening a test chemical to determine if it has activity similar to a known chemical, wherein said method comprises:
- (a) cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding a nuclear receptor or said nuclear receptor ligand binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said known chemical;
 - (b) growing a first portion of said cotransfected cells in the presence of said test chemical;
 - (c) growing a second portion of said cotransfected cells in the absence of said chemical; and
 - (d) determining the level of expression of said reporter gene in each portion of cells; wherein if the level of expression of said reporter gene in said first portion of said cells is greater than the level of expression in said second portion of said cells then said test chemical has activity similar to said known chemical.
26. The method of claim 25 wherein said co-regulatory protein is 35 kDa.
27. The method of claim 25 wherein said co-regulatory protein comprises SEQ ID NO:9.
28. The method of claim 25 wherein said co-regulatory protein consists of SEQ ID NO:8.
29. The method of claim 25 wherein said nuclear receptor ligand binding domain and said known chemical are selected from the sets of (i) ER and estradiol, (ii) GR and deoxycorticosterone, (iii) AR and dihydrotestosterone, (iv) PR and progesterone, (v) TR and T3, (vi) RAR and all-*trans*-retinoic acid, and (vii) RXR and 9-*cis*-retinoic acid.

30. The method of claim 25 wherein expression of said reporter gene causes production of histidine.
31. The method of claim 25 wherein said reporter gene is CAT.
32. The method of claim 25 wherein said cells are yeast cells or human cells.
33. The method of claim 25 wherein said nuclear receptor is capable of binding to an aromatase gene.
34. A method of determining a concentration of a ligand or a hormone in a tissue sample, wherein said method comprises:
- (a) cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a nucleic acid comprising a gene encoding a nuclear receptor or said nuclear receptor ligand binding domain to produce cotransfected cells which synthesize said co-regulatory protein and said nuclear receptor or said nuclear receptor ligand binding domain, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to said nuclear receptor or to said nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said ligand or hormone;
 - (b) preparing an extract of said tissue sample;
 - (c) growing a first portion of said cotransfected cells in the presence of said tissue extract;
 - (d) growing second portions of said cotransfected cells in the presence of known concentrations of said ligand or hormone; and
 - (e) determining the level of expression of said reporter gene in each portion of cells; wherein the concentration of said ligand or said hormone in said tissue extract can be determined by comparison of the expression level of said reporter gene in said first portion with the expression levels of said reporter gene in said second portions.
35. The method of claim 34 wherein said co-regulatory protein is 35 kDa.

36. The method of claim 34 wherein said co-regulatory protein comprises SEQ ID NO:9.
37. The method of claim 34 wherein said co-regulatory protein consists of SEQ ID NO:8.
38. The method of claim 34 wherein said nuclear receptor ligand binding domain and said ligand or hormone are selected from the sets of (i) ER and estradiol, (ii) GR and deoxycorticosterone, (iii) AR and dihydrotestosterone, (iv) PR and progesterone, (v) TR and T3, (vi) RAR and all-*trans*-retinoic acid, and (vii) RXR and 9-*cis*-retinoic acid.
39. The method of claim 34 wherein expression of said reporter gene causes production of histidine.
40. The method of claim 34 wherein said reporter gene is CAT.
41. The method of claim 34 wherein said cells are yeast cells or human cells.
42. The method of claim 34 wherein said nuclear receptor is capable of binding to an aromatase gene.
43. A method of screening for a protein which interacts with a chemical, wherein said method comprises:
(a) cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a library of nucleic acids to produce a library of cotransfected cells which synthesize said co-regulatory protein and said library of nucleic acids, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to a nuclear receptor or to a nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said chemical;
(b) growing a first portion of said cotransfected cells in the absence of said chemical;

(c) growing a second portion of said cotransfected cells in the presence of said chemical, wherein said second portion is a replicate of said first portion; and

(d) comparing the level of expression of said reporter gene in individual colonies of said first portion and in said second portion;

wherein if a colony of said second portion expresses said reporter gene at a higher level than its corresponding replicate colony in said first portion then said colony comprises a gene from said library encoding a protein which interacts with said chemical.

44. The method of claim 43 wherein said co-regulatory protein is 35 kDa.
45. The method of claim 43 wherein said co-regulatory protein comprises SEQ ID NO:9.
46. The method of claim 43 wherein said co-regulatory protein consists of SEQ ID NO:8.
47. The method of claim 43 wherein said nuclear receptor ligand binding domain and said ligand or hormone are selected from the sets of (i) ER and estradiol, (ii) GR and deoxycorticosterone, (iii) AR and dihydrotestosterone, (iv) PR and progesterone, (v) TR and T3, (vi) RAR and all-*trans*-retinoic acid, and (vii) RXR and 9-*cis*-retinoic acid.
48. The method of claim 43 wherein expression of said reporter gene causes production of histidine.
49. The method of claim 43 wherein said reporter gene is CAT.
50. The method of claim 43 wherein said cells are yeast cells or human cells.
51. The method of claim 43 wherein said nuclear receptor is capable of binding to an aromatase gene.

52. A method of screening for a protein which interacts with a chemical, wherein said method comprises:

(a) cotransfecting cells with i) a gene which expresses a co-regulatory protein comprising SDPPSPS (SEQ ID NO:5) and ii) a library of nucleic acids to produce a library of cotransfected cells which synthesize said co-regulatory protein and said library of nucleic acids, and further wherein said cotransfected cells comprise a reporter gene the expression of which depends upon said co-regulatory protein binding to a nuclear receptor or to a nuclear receptor ligand binding domain, and further wherein said co-regulatory protein binds to said nuclear receptor or to said nuclear receptor ligand binding domain in the presence of said chemical;

(b) growing colonies of said cotransfected cells in the presence of said chemical; and

(c) determining the level of expression of said reporter gene in individual colonies of cells;

wherein a colony of cells which expresses said reporter gene comprises a gene from said library encoding a protein which interacts with said chemical.

ABSTRACT OF THE DISCLOSURE

Assays are presented for screening for chemicals which affect the binding between proteins comprising an SH3 binding motif and nuclear receptor proteins. PNRC (Proline-rich Nuclear Receptor Co-regulatory protein) is a co-regulatory protein comprising an SH3 binding motif and was identified using bovine SF1 as the bait in a yeast two-hybrid screening of a human mammary gland cDNA expression library. This nuclear receptor coactivator binds to several nuclear receptors including those which regulate the aromatase gene which is involved in breast cancer. Compounds which affect the binding of PNRC to nuclear receptors can affect the expression of the aromatase gene as well as of other genes whose expression is under the control of nuclear receptors to which PNRC binds. PNRC is unique in that it has a molecular weight of 35 kDa, significantly smaller than most of the co-regulatory proteins reported so far, and it is proline-rich. In yeast two-hybrid assays, PNRC interacted with the orphan receptors SF1 and ERR α 1 in a ligand-independent manner. PNRC was also found to interact with the ligand-binding domains (LBDs) of all the nuclear receptors tested including ER, AR, PR, TR, RAR, and RXR in a ligand-dependent manner. A 23-amino acid region, aa 278-300, in the carboxy-terminal region was shown to be critical and sufficient for the interaction with nuclear receptors. This region is proline-rich and contains an SH3-binding motif, S-D-P-P-S-P-S (SEQ ID NO:5).

cDNA expression vectors	Growth on	
	SD/-Leu/-Trp	SD/-Leu/-Trp/-His+3-AT
Gal4DB +Gal4AD	+	-
Gal4DB-SF1+Gal4AD	+	-
Gal4DB-SF1+AD-PNRC	+	+
hLCDB + AD-PNRC	+	-
Gal4DB-ERR α 1 + Gal4 AD	+	-
Gal4DB-ERR α 1 + AD-PNRC	+	+
Gal4DB-ER _{HBD} + Gal4 AD	+	-
Gal4DB-ER _{HBD} + AD-PNRC (E ₁ -)	+	-
Gal4DB-ER _{HBD} + AD-PNRC (E ₂ *+)	+	+
Gal4DB-GR _{HBD} + Gal4AD	+	-
Gal4DB-GR _{HBD} + AD-PNRC (C-)	+	-
Gal4DB-GR _{HBD} + AD-PNRC (C*+)	+	+
Gal4DB-PR _{HBD} + Gal4AD	+	-
Gal4DB-PR _{HBD} +AD-PNRC (P-)	+	-
Gal4DB-PR _{HBD} + AD-PNRC (P*+)	+	+
Gal4DB-AR _{HBD} + Gal4AD	+	-
Gal4DB-AR _{HBD} + AD-PNRC (T-)	+	-
Gal4DB-AR _{HBD} + AD-PNRC (T*+)	+	-
Gal4DB-TR _{HBD} + Gal4AD	+	-
Gal4DB-TR _{HBD} + AD-PNRC (T ₃ -)	+	-
Gal4DB-TR _{HBD} + AD-PNRC (T ₃ *+)	+	+
Gal4DB-RAR _{HBD} +Gal4AD	+	-
Gal4DB-RAR _{HBD} +AD-PNRC (RA-)	+	-
Gal4DB-RAR _{HBD} +AD-PNRC (RA*+)	+	+
Gal4DB-RXR _{HBD} +Gal4AD	+	-
Gal4DB-RXR _{HBD} +AD-PNRC (9c-RA-)	+	-
Gal4DB-RXR _{HBD} +AD-PNRC (9c-RA*+)	+	+

*E2-Estradiol, 100 nM; C-deoxycorticosterone, 10 μ M; P-progesterone, 500 nM; T-dihydrotestosterone, 100 nM; T3-10 μ M; RA-all-trans-retinoic acid, 10 μ M; 9c-RA-9-cis-retinoic acid, 10 μ M.

FIG. 1A

006740" 5022550




FIG. 1B




FIG. 1C

006740"50225560

Relative CAT activity, CPM/ μ g cell extract




FIG. 2

	GST-PNRC	
Input	GST	
	aa270- 327	aa278- 300

FIG. 3A

	GST-PNRC	
Input	GST	
	aa270- 327	aa278- 300

FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C

00640" 50/2550




FIG. 4D




FIG. 5A

β -Gal Activity (Units)




FIG. 5B




FIG. 6

SEQUENCE LISTING

<110> Chen, Shiuan
Zhou, Dujin

<120> DRUG SCREENING USING A PROLINE-RICH NUCLEAR RECEPTOR
CO-REGULATORY PROTEIN/NUCLEAR RECEPTOR CO-EXPRESSION
SYSTEM

<130> 2124-311

<140> To be assigned

<141> 2000-04-19

<150> U.S. 60/129,873

<151> 1999-04-19

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Sense primer.

<400> 1

gccgaattcg gggagggcag gggatgaagtg

30

<210> 2

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Antisense
primer.

<400> 2

ggcgtcgacg gacctcaga ctgtggcagg gaaaccctc

39

<210> 3

<211> 12

<212> DNA

<213> Homo sapiens

<400> 3

ccaaggtcag aa

12

<210> 4

<211> 5

<212> PRT

<213> Homo sapiens

<400> 4

Leu Lys Thr Leu Leu

1

5

006740"5022550

<400> 5
Ser Asp Pro Pro Ser Pro Ser
1 5

```
<220>  
<221> MUTAGEN  
<222> (3)  
<223> This residue has been changed from a proline.
```

```
<220>
<221> MUTAGEN
<222> (6)
<223> This residue has been changed from a proline.
```

<400> 6
Ser Asp Ala Pro Ser Ala Ser
1 5

```
<210> 7
<211> 2061
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> CDS
<222> (114)..(1094)
```

<400> 7																
tggttcgcgca	tctttctcagg	ctctctctagc	agcatccatc	gccgccaccc	tatctttcaat											60
ggcttcacat	tctctctctc	tcttcgttgc	tgagcgacaa	gcttctctagc	gct	atg										116
						Met										1
act	gtc	gtc	tcc	gtc	ccg	cag	cgg	gag	ccg	ctc	gtc	ctg	ggc	ggc	cgc	164
Thr	Val	Val	Ser	Val	Pro	Gln	Arg	Glu	Pro	Leu	Val	Leu	Gly	Gly	Arg	
			5					10					15			
ctt	gcg	ccg	ctt	ggc	ttt	tcc	tcc	cga	ggc	tac	ttt	ggg	gcc	ctc	ccg	212
Leu	Ala	Pro	Leu	Gly	Phe	Ser	Ser	Arg	Gly	Tyr	Phe	Gly	Ala	Leu	Pro	
			20				25					30				
atg	gtg	acc	acg	gct	ccg	cct	cct	tta	ccc	cgg	atc	ccg	gac	ccc	cgg	260
Met	Val	Thr	Thr	Ala	Pro	Pro	Pro	Leu	Pro	Arg	Ile	Pro	Asp	Pro	Arg	
	35					40					45					
gca	ctg	ccc	ccg	acc	ctc	ttc	ctc	cct	cat	ttc	cta	ggg	gga	gat	ggc	308
Ala	Leu	Pro	Pro	Thr	Leu	Phe	Leu	Pro	His	Phe	Leu	Gly	Gly	Asp	Gly	
50					55					60					65	

cgc	tgt	ctg	acc	ccc	cag	cct	cgc	gct	cca	gca	gct	ctg	ccc	aac	cgc	356
Pro	Cys	Leu	Thr	Pro	Gln	Pro	Arg	Ala	Pro	Ala	Ala	Leu	Pro	Asn	Arg	
				70					75					80		
agc	ctc	gcc	gtg	gcg	gga	ggc	act	cct	cgg	gca	gcg	ccg	aag	aag	cgg	404
Ser	Leu	Ala	Val	Ala	Gly	Gly	Thr	Pro	Arg	Ala	Ala	Pro	Lys	Lys	Arg	
			85					90					95			
cga	aag	aag	aag	gtg	cgg	gcc	agc	ccc	gca	ggg	cag	ctg	ccc	agc	cgc	452
Arg	Lys	Lys	Lys	Val	Arg	Ala	Ser	Pro	Ala	Gly	Gln	Leu	Pro	Ser	Arg	
			100				105					110				
ttc	cac	cag	tac	cag	cag	cac	cgg	ccg	agt	ctg	gag	ggc	ggc	cgg	agc	500
Phe	His	Gln	Tyr	Gln	Gln	His	Arg	Pro	Ser	Leu	Glu	Gly	Gly	Arg	Ser	
	115					120					125					
ccc	gcg	acc	ggc	ccg	agc	gga	gcg	cag	gag	gtc	ccg	ggc	ccg	gcc	gcc	548
Pro	Ala	Thr	Gly	Pro	Ser	Gly	Ala	Gln	Glu	Val	Pro	Gly	Pro	Ala	Ala	
130					135					140					145	
gcc	ttg	gcc	ccg	agt	cct	gca	gcc	gca	gcc	ggc	acg	gag	gga	gcc	agc	596
Ala	Leu	Ala	Pro	Ser	Pro	Ala	Ala	Ala	Ala	Gly	Thr	Glu	Gly	Ala	Ser	
				150					155					160		
ccc	gac	ctt	gcc	ccg	ctg	cgg	ccc	gcg	gct	ccc	ggc	caa	acc	ccc	ctc	644
Pro	Asp	Leu	Ala	Pro	Leu	Arg	Pro	Ala	Ala	Pro	Gly	Gln	Thr	Pro	Leu	
			165					170					175			
agg	aaa	gag	gtt	tta	aaa	tca	aag	atg	gga	aaa	tcg	gag	aaa	att	gcc	692
Arg	Lys	Glu	Val	Leu	Lys	Ser	Lys	Met	Gly	Lys	Ser	Glu	Lys	Ile	Ala	
		180					185					190				
ctt	ccc	cat	ggc	cag	ctt	gtt	cat	ggt	ata	cac	ttg	tat	gag	caa	cca	740
Leu	Pro	His	Gly	Gln	Leu	Val	His	Gly	Ile	His	Leu	Tyr	Glu	Gln	Pro	
	195					200					205					
aag	ata	aac	aga	cag	aaa	agc	aaa	tat	aac	ttg	cca	cta	acc	aag	atc	788
Lys	Ile	Asn	Arg	Gln	Lys	Ser	Lys	Tyr	Asn	Leu	Pro	Leu	Thr	Lys	Ile	
210					215					220					225	
acc	tct	gca	aaa	aga	aat	gaa	aac	aac	ttt	tgg	cag	gat	tct	gtt	tca	836
Thr	Ser	Ala	Lys	Arg	Asn	Glu	Asn	Asn	Phe	Trp	Gln	Asp	Ser	Val	Ser	
				230					235					240		
tct	gac	aga	att	cag	aag	cag	gaa	aaa	aag	cct	ttt	aaa	aat	acc	gag	884
Ser	Asp	Arg	Ile	Gln	Lys	Gln	Glu	Lys	Lys	Pro	Phe	Lys	Asn	Thr	Glu	
			245					250					255			
aac	att	aaa	aat	tcg	cat	ttg	aag	aaa	tca	gca	ttt	cta	act	gaa	gtg	932
Asn	Ile	Lys	Asn	Ser	His	Leu	Lys	Lys	Ser	Ala	Phe	Leu	Thr	Glu	Val	
		260					265					270				
agc	caa	aag	gaa	aat	tat	gct	ggg	gca	aag	ttt	agt	gat	cca	cct	tct	980
Ser	Gln	Lys	Glu	Asn	Tyr	Ala	Gly	Ala	Lys	Phe	Ser	Asp	Pro	Pro	Ser	
	275					280					285					
cct	agt	gtt	ctt	cca	aag	cct	cct	agt	cac	tgg	atg	gga	agc	act	gtt	1028
Pro	Ser	Val	Leu	Pro	Lys	Pro	Pro	Ser	His	Trp	Met	Gly	Ser	Thr	Val	
290					295					300					305	
gaa	aat	tcc	aac	caa	aac	agg	gag	ctg	atg	gca	gta	cac	tta	aaa	acc	1076
Glu	Asn	Ser	Asn	Gln	Asn	Arg	Glu	Leu	Met	Ala	Val	His	Leu	Lys	Thr	
				310					315					320		

ctc ctc aaa gtt caa act tagatttcag atttcagtat gtgtgtaaaa 1124
 Leu Leu Lys Val Gln Thr
 325

cataatTTTT cccatatccc tggactcttg agaaaattgg tacagaaatg gaaatttgcc 1184
 ttgttgcaac atacaattgc aaaagatgag tttaaaaaat tacatacaaa cagcttgat 1244
 tatatTTTTat attttgtaaa tactgtatac catgtattat gtgtatattg ttcatacttg 1304
 agaggatat tatagTTTTg ttatgaaagt atgtatTTTTg ccctgcccac attgcaggtg 1364
 ttttgatat atacaatgga taaatTTTTaa gtgtgtgcta aggcacatgg aagaccgatt 1424
 ttatttgcac aagggtactga gattTTTTtC aagaaacagc tgtcaaactc caagggtgaag 1484
 atctaaaatgt gaacagtTTa ctaatgcact actgaagttt aaatctgtgg cacaatcaat 1544
 gtaagcatgg ggtttgTTtC tctaaattga tttgtaactc gaaattactg aacaactcct 1604
 attcccatTTt ttgctaaact caatttctgg ttttggtata tatccattcc agcttaatgc 1664
 ctctaattTTt aatgccaca aaattggttg taatcaaatt ttaaaataat aataatttg 1724
 cccccctTTt taaaatagtc ttgactcttt gtgtgtgact gtttctcatg tttgaatgtg 1784
 tgactaggag atgattttgt gtggttgat ttttttgact tctactttac tggctgagt 1844
 tgagccgcca tgctggcca taatctacat tttcttacca ggagcagcat tgaggTTTTt 1904
 gagcatagta cttgactact ctagaggctg agacgggagc atctcttgag cctgagaagt 1964
 ggagattgca attgagctag gatcaggcca ctgcactcca gcctgggtaa cagacgctgt 2024
 ctcaaaaaaa aggccaagag aaagtaaggg agacaga 2061

<210> 8
 <211> 327
 <212> PRT
 <213> Homo sapiens

<400> 8
 Met Thr Val Val Ser Val Pro Gln Arg Glu Pro Leu Val Leu Gly Gly
 1 5 10 15
 Arg Leu Ala Pro Leu Gly Phe Ser Ser Arg Gly Tyr Phe Gly Ala Leu
 20 25 30
 Pro Met Val Thr Thr Ala Pro Pro Pro Leu Pro Arg Ile Pro Asp Pro
 35 40 45
 Arg Ala Leu Pro Pro Thr Leu Phe Leu Pro His Phe Leu Gly Gly Asp
 50 55 60
 Gly Pro Cys Leu Thr Pro Gln Pro Arg Ala Pro Ala Ala Leu Pro Asn
 65 70 75 80
 Arg Ser Leu Ala Val Ala Gly Gly Thr Pro Arg Ala Ala Pro Lys Lys
 85 90 95
 Arg Arg Lys Lys Lys Val Arg Ala Ser Pro Ala Gly Gln Leu Pro Ser
 100 105 110

005440"5025550

Arg Phe His Gln Tyr Gln Gln His Arg Pro Ser Leu Glu Gly Gly Arg
 115 120 125
 Ser Pro Ala Thr Gly Pro Ser Gly Ala Gln Glu Val Pro Gly Pro Ala
 130 135 140
 Ala Ala Leu Ala Pro Ser Pro Ala Ala Ala Gly Thr Glu Gly Ala
 145 150 155 160
 Ser Pro Asp Leu Ala Pro Leu Arg Pro Ala Ala Pro Gly Gln Thr Pro
 165 170 175
 Leu Arg Lys Glu Val Leu Lys Ser Lys Met Gly Lys Ser Glu Lys Ile
 180 185 190
 Ala Leu Pro His Gly Gln Leu Val His Gly Ile His Leu Tyr Glu Gln
 195 200 205
 Pro Lys Ile Asn Arg Gln Lys Ser Lys Tyr Asn Leu Pro Leu Thr Lys
 210 215 220
 Ile Thr Ser Ala Lys Arg Asn Glu Asn Asn Phe Trp Gln Asp Ser Val
 225 230 235 240
 Ser Ser Asp Arg Ile Gln Lys Gln Glu Lys Lys Pro Phe Lys Asn Thr
 245 250 255
 Glu Asn Ile Lys Asn Ser His Leu Lys Lys Ser Ala Phe Leu Thr Glu
 260 265 270
 Val Ser Gln Lys Glu Asn Tyr Ala Gly Ala Lys Phe Ser Asp Pro Pro
 275 280 285
 Ser Pro Ser Val Leu Pro Lys Pro Pro Ser His Trp Met Gly Ser Thr
 290 295 300
 Val Glu Asn Ser Asn Gln Asn Arg Glu Leu Met Ala Val His Leu Lys
 305 310 315 320
 Thr Leu Leu Lys Val Gln Thr
 325

<210> 9
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 9
 Asn Tyr Ala Gly Ala Lys Phe Ser Asp Pro Pro Ser Pro Ser Val Leu
 1 5 10 15

Pro Lys Pro Pro Ser His Trp
 20